Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multifunctional theranostic nanoplatform based on HER2-specific liposomes loaded with IR783 for simultaneous PTT/PDT therapy and optical bioimaging.

Nanomedicine : nanotechnology, biology, and medicine·2026

Same author

Uptake and Retention of Laser-synthesized Boron Nanoparticles in Tumor Cells and Fibroblasts.

Doklady. Biochemistry and biophysics·2026

Same author

The effect of dimeric bisbenzimidazoles on the activity of DNA repair enzymes TDP1, TDP2, PARP1 and PARP2.

Vavilovskii zhurnal genetiki i selektsii·2026

Same author

Synthesis and Pharmacokinetics of Nanosized NH<sub>2</sub>‑UiO‑66 (Zr) Metal-Organic Frameworks.

Doklady. Biochemistry and biophysics·2026

Same author

Targeted Radionuclide Detection of Malignant Tumors Using Affibody.

Acta naturae·2026

Same author

Targeted Nanoliposomes for the Delivery of Boronophenylalanine into HER2-Positive Cells.

Acta naturae·2025

Search research articles

Related Experiment Video

Updated: Mar 27, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

[Supramolecular Agents for Theranostics].

S M Deyev, E N Lebedenko

Bioorganicheskaia Khimiia

|January 15, 2016

Summary

Researchers developed a versatile platform for creating supramolecular theranostic agents. This system enables targeted imaging and elimination of cancer cells using novel hybrid structures for personalized medicine.

Area of Science:

Biotechnology
Nanotechnology
Molecular Medicine

Background:

Supramolecular chemistry offers novel approaches for developing advanced therapeutic and diagnostic agents.
Current theranostic strategies require versatile platforms for integrating diverse functional modules.

Purpose of the Study:

To summarize recent advancements in creating a modular platform for supramolecular theranostic agents.
To exemplify the platform's utility in developing multifunctional agents for cancer cell imaging and elimination.

Main Methods:

Utilizing the barnase:barstar protein system as an adapter for constructing hybrid structures.
Incorporating highly specific peptides and mini-antibodies as targeting modules.
Employing various nanoparticles (e.g., quantum dots, nanogold, magnetic nanoparticles) and recombinant proteins as imaging and therapeutic agents.

More Related Videos

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Mar 27, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

Main Results:

Demonstrated the successful construction of multifunctional hybrid agents for cancer theranostics.
Showcased the integration of targeting modules with diverse imaging and damaging agents.
Established a versatile platform adaptable for various therapeutic and diagnostic applications.

Conclusions:

The developed modular platform facilitates the creation of targeted, multifunctional supramolecular theranostic agents.
This approach holds significant promise for advancing selective and effective cancer treatments.
Opens new avenues for personalized medicine through tailored theranostic compound development.